Central coordination as an alternative for local coordination in a multicenter randomized controlled trial: the FAITH trial experience

Table 4 Data concerning the pre-trial screening period of countries participating in the FAITH trial

	NL (N = 4)	CA (N = 8)	US (N = 14)	P-value
Screening period (days)	55 (51 - 92)	60 (56 - 74)	50 (20 - 69)	0.121
Eligible patients (N)	4 (3 - 6)	4 (1 - 10)	3 (1 - 6)	0.571
Total patients (N)	6 (6 - 9)	15 (15 - 34)	6 (5 - 11)	0.006^a
Eligible patients (N per month)	2.0 (1.7 - 2.4)	1.5 (0.7 - 4.1)	2.2 (1.1 - 5.0)	0.786
Total patients (N per month)	3.3 (3.0 - 3.6)	7.5 (5.6 - 17.4)	5.0 (3.1 - 8.2)	0.016 ^b
Proportion eligible patients (% of total)	63 (53 - 67)	14 (10 - 40)	48 (29 - 71)	0.062

NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites per country that data were available for.
Data are presented as median with P₂₅-P₇₅ given between brackets.
Statistics were calculated using the Kruskal-Wallis ANOVA.
Post-hoc pair wise comparisons were performed using Mann-Whitney U-test: ^a Statistical significance was reached when comparing NL vs. CA (p = 0.009), and CA vs. USA (p = 0.004), NL vs. USA: not significant. ^b Statistical significance was reached when comparing NL vs. CA (p = 0.007), other groups: not significant.

ISSN: 1745-6215